February 2018 Work Group Recaps:

For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at http://www.ncpdp.org/members/members_wg_info.aspx?wgid=wgmc.

Work Group 1 Telecommunication

DERFs/ECLs Reviewed:
- DERF 001559/ECL 000248 was recommended for MC to approve with modifications.
- DERF 001579/ECL 000255 was recommended for MC to approve with modifications.
- DERF 001580/ECL 000256 was recommended for MC to approve.
- DERF 001581/ECL 000257 was recommended for MC to approve with modifications.
- DERF 001582 was approved.

Old Business:
- Use of Quantity Prescribed (460-ET) in the Telecommunication Standard claim billing - Note this field would be required for Part D Schedule II Controlled Substance claims; however, the use of this field is not limited to Part D claims.
  - Telecom D.0 and all versions from that point have been updated (November 2012).
  - 03/2014 NCPDP received a response from HHS to the 03/2013 letter. The change will go through NPRM and Final Rule processes.
    - NCPDP has asked the industry to provide input on the implementation timeframe before the NPRM is published.
    - NCPDP has asked for a timeframe of NPRM publication.
  - 06/2014 Update: OESS has responded that an NPRM including Quantity Prescribed and SCRIPT electronic prior authorization is going through the review process.
  - WG1 Telecommunication FAQ Task Group brought forward a recommendation timeframe for Quantity Prescribed regulation implementation for OESS.
  - 07/21/2015 Update from NSG: The new target date for this regulation is early 2016.
  - 01/21/2016 Update from NSG: This policy item is undergoing the rulemaking process, and at this time a specific timeframe cannot be provided.
  - 04/11/2016 Update from NSG: The request is still in the rule making stage, so at this point CMS cannot provide a formal comment on its status.
  - 07/25/2016 Update from NSG: Additional questions were received and documentation from 2010, 2012 and 2013 was provided to answer the questions.
  - 10/14/2016 Update from NSG: This policy is in the rulemaking stage, there should be an NPRM out by Mid-2017.
  - 02/2017: Still tracking to a mid-2017 date.
  - 08/2017: Still tracking to a late summer 2017 NPRM.

Task Groups:
- The Telecommunication FAQ Task Group reviewed five questions and a proposed modification to the Version D.0 Editorial document by the MED sub-task group. The task group proposed and the work group agreed to create a WG1 task group, Expand Dollar Fields, to address the increase of dollar fields. The modification to the Version D.0 Editorial document was approved.
  - The Morphine Equivalent Dosing (MED) Sub-Task Group drafted opioid limitation guidance. The guidance includes usage of new and existing reject codes, reject code
combinations as well as override mechanisms and the use of prior authorization numbers. The group reviewed the Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program NPRM and provided suggested comments.

- The FAQ Controlled Substance Guidance Update Sub-Task Group is focused on developing Version D.0 use/test cases related to short filling/partially filling C2-5 drugs. The group is also drafting questions for CMS relative to the DEA and CARA inconsistencies in script validity. The group will be creating a guidance document and coordinating with other applicable task groups to ensure the recommendations work together.

- The Coordination of Benefits Task Group reviewed and answered two questions which resulted in a DERF and a request to add a FAQ to the Version D.0 Editorial Document which was approved by the WG. The group will begin developing F2 transition guidance and educational materials.

- The Information Reporting Problems Task Group reviewed and proposed revisions to the Medicare Prescription Drug Benefit Manual Chapter 14-Coordination of Benefits, reviewed FAQs and sent questions to CMS. The group reinstated the SPAP/ADAP Data Exchange Sub-Task Group as CMS announced a new HPMS module. The NCPDP Best Practices Guide for Managing Med D OHI document was submitted to the Standardization Committee for review and approval. The group will continue to review and revise the current Part D COB white paper.

- The Post Adjudication Task Group did not meet this quarter.

- The Definition of a Valid Prescriber Task Group drafted comments on the January 01, 2019 effective date for the precluded provider process, 24-hour follow-up for non-NPI prescriber IDs, file layout, order of edits for other excluded provider files and uniqueness of exclusion criteria, provisional fill process, recommendation to eliminate POS provisional fill and incorporate post-dated precluded provider effective date process that would incorporate the appeal process and 90 day grace period, POS adjudication would always reject claims where the claim DOS is equal to or greater than the precluded provider effective date, Medicare/Medicaid dual eligible processes, PDE file layout changes and individual versus entity exclusions.

- The Part D Supplemental Payment Reporting Task Group reviewed changes to Chapter 14 and found no impact to reporting. The group also reviewed missing emails.

- The Eligibility Verification Enhancements Task Group did not meet this quarter.

- The Benefit Integration Task Group continued working on the Benefit Synchronization transaction.

- The Standardized Subrogation Task Group did not meet this quarter.

- The Usage of Submission Clarification Codes (SCC) Task Group did not meet this quarter.

- The Compound Task Group did not meet this quarter.

- The Upstream Reporting of Copay Assistance Task Group is creating a paper to document the results of the task group research; not to provide recommendations or solutions. The research is exploring options for providing a record of payment made by supplemental payers in order for primary/prior payers to maintain accurate accumulator values.

New Business:

- **DSMO Change Requests:** Received an update on the status of the DSMO Change Request 1201 and 1202.

- **Task Group Leader Certificates of Appreciation** were presented by the WG1 Co-Chairs to the WG1 Task Group Leads.

Work Group 2 Product Identification

Old Business:
• Tom Bizzaro of First Data Bank (FDB) provided comments on health policy focusing on upcoming meetings of ONC’s Health Information Technology Advisory Committee (HITAC); the opioid crisis and biosimilar naming.

• Tammy Powell of the National Library of Medicine (NLM) provided an update on RxNorm and DailyMed.

Task Groups:

• The **Structure Product Labeling Activities Task Group** had no new activity to report this quarter.

• The **Product Review and Billing Unit Exception Task Group** reviewed issues resulting from changes to existing products or release of new products. The task group:
  o Reviewed and submitted to WG2 for adjudication six new QUIC forms: (see final adjudication determination by the WG in this report).
    ▪ QUIC #201709 BYDUREON BCise
    ▪ QUIC #201710 Cefaly
    ▪ QUIC #201711 CycloTENS
    ▪ QUIC #201712 Abilify Mycite
    ▪ QUIC #201801 RELiZORB
    ▪ QUIC #201802 Insmed New Product
  o Reviewed five products via email to determine the billing unit and package size.
  o For October, November, and December 2017, 2,950 and zero changed billing unit indexing files were generated by FDA based on the files received by the compendia. The compendia group has reconciled the 11 NDCs with discrepancies.
  o Implemented a grid to document the billing unit decisions agreed to via email.

• The **SPL REMS Requirements Task Group** did not meet this quarter. The co-lead provided the following information:
  o No new REMS SPL submissions have been approved.
  o On December 13, 2017, FDA posted notification of a public hearing whose purpose it is to receive stakeholder input on how FDA might, under REMS authority, improve the safe use of opioid analgesics by curbing overprescribing and potential new addictions and limiting misuse and abuse.
  o FDA Commissioner Gottlieb announced in November 2017 steps that the Agency will take to ensure generic drug access to shared REMS.
  o FDA opened a docket in October 2017 to receive recommendations on the design of the REMS Platform Standards Initiative (previously the Common REMS Platform Initiative), as well as methods and best practices for its construction.
  o FDA has published NCI thesaurus concept codes (OID: 2.16.840.1.113883.3.26.1.1) for use in codifying REMS and recently updated its REMS Document Template to simply preparation of REMS using SPL and drive further adoption of the standard.

• The **Dates Associated with Pharmaceutical Products Task Group** completed a white paper which describes the definitions of the data elements in the different market segments and the life cycle of a product.

• The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** did not meet this quarter. The co-leads are contemplating next steps on engaging the FDA.

• The **Application of the Billing Unit Standard Clarification Task Group** completed review and categorization of products which were subjects of QUIC forms. The task group is drafting language for each category related to the exceptions in preparation for creating a guidance document.

• The **WG2/WG11 Harmonization of Prescribing and Dispensing Units Task Group** had no new activity to report this quarter.
• Received an update from the **WG11 REMS Workflow to Transactions Task Group.**

• Notified of the disbanding of the **MC 2D Barcode Implementation Task Group.**

**New Business:**

• **New QUIC Form Review:**
  
  **QUIC #201709 BYDUREON BCise**
  
  **BU = ML with a package size of .85 per section 5.2.2 of the Billing Unit Standard.**
  
  **QUIC #201710 Cefaly**
  
  **BU = EA with a package size of 1. A FAQ will be drafted to support how to determine the BU for TENS devices with and without drugs.**
  
  **QUIC #201711 CycloTENS**
  
  **BU = EA with a package size of 31 (30 tablets + 1 TNS unit) for the starter kit and a package size of 30 (tablets) for the refill pack. A FAQ will be drafted to support how to determine the BU for TENS devices with and without drugs.**
  
  **QUIC #201712 Abilify Mycite**
  
  **BU = EA with a total quantity of 30. A FAQ will be drafted to address technology and other devices packaged with consumable drug product.**

• **Task Group Leader Certificates of Appreciation** were presented by the WG2 Co-Chairs to the WG2 Task Group Leads.

• Boris Meyerson, EVP, Business Operations, Encore Dermatology, gave a presentation about a new product, **IMPOYZ™ (clobetasol propionate) cream, 0.025%.**

• Neal Muni, President and CEO, CutisPharma, Inc., gave a presentation about a new product, **FIRVANQ™.**

**Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards**

**Task Groups:**

• The **Medical Rebate Standard Task Group** did not meet this quarter.

• The **Medicaid Drug Rebate Program Task Group** continues to work on the development of a white paper, **Medicaid Drug Rebate Program - Challenges Across the Industry.** The white paper will provide the pharmaceutical industry an overview of the Medicaid Drug Rebate Program (MDRP) and information related to disputing invoiced claims, 340B claims submitted for rebate, terminated claims, claim level data necessary to validate summary level invoices and high level recommendations which would benefit the overall MDRP processes.

• The **Manufacturer Rebate Standard Task Group.** The **Manufacturer Rebate Utilization, Plan, Formulary, Market Basket, and Reconciliation Flat File Standard Implementation Guide Version 07.02** was published in January 2018 and is available for download through Standards Lookup on the member portal. During the last two quarters the task group has focused on Outcomes Based Contracting. Before a recommendation is made as to whether there could be an additional data type or standard within WG7 to help support this contracting between trading partners, the task group will develop new content for the **NCPDP Reference Guide to Rebate Processing, Validation, and Dispute Resolution.**
Specialty Pharmacy Data Exchange Sub-Task Group. The *Specialty Pharmacy Data Reporting Standard Implementation Guide* was published in January 2018 and is available for download through Standards Lookup on the member portal.

- **WG9 340B Task Group** completed their work on the spreadsheet which identifies current industry methods of capturing the data on 340B activity and the opportunities and drawbacks of each method by stakeholder perspective. That information will be used to augment and update the [340B Information Exchange Reference Guide v1.0](https://example.com) published in 2011.

New Business:

- **Task Group Leader Certificates of Appreciation** were presented by the WG7 Co-Chairs to the WG7 Task Group Leads.

**Work Group 9 Government Programs**

Task Groups:

- The [Prescription Drug Monitoring Program (PDMP) Task Group](https://example.com) reviewed Controlled Substance Reporting (CI-CII) requirements as a standalone standard to supplement the B1 real-time reporting to the PDMP Facilitator as outlined in the white paper, *NCPDP’s Recommendations for an Integrated, Interoperable Solution to Ensure Patient Safe Use of Controlled Substances*. The task group continued to work on the development of a PDMP Reporting Standard to report fields to the PDMP facilitator and/or the State PDMP which includes new fields from the Telecommunication Standard vF2 and fields required by states currently or in the future. The task group also reviewed the [State PMP Tracking Document](https://example.com) and updated PMP information for the following states: Alabama, Florida, Illinois, Kansas, Maryland, Maine, Missouri, Nevada, Oklahoma, and Wisconsin.

- The [340B Task Group](https://example.com) completed their work on the spreadsheet which identifies current industry methods of capturing the data on 340B activity and the opportunities and drawbacks of each method by stakeholder perspective. That information will be used to augment and update the [340B Information Exchange Reference Guide v1.0](https://example.com) published in 2011.

- The [Government Programs Encounter Reporting Standards Task Group](https://example.com) completed review of approximately 30 out of 80 remaining fields in a subset including Eligibility, Accumulator, Coordination of Benefits, Pricing, Compound and potential new fields. The task group is awaiting feedback on the extent of COB data use from California, Texas and New York.

- The [Medicaid Subrogation FAQ Task Group](https://example.com) did not meet as no new questions were received.

- The [Medicaid Best Practices Using NCPDP Standards to Implement Reimbursement Methodology Task Group](https://example.com) did not receive any new questions or comments have been received the past two quarters related to guidance in implementing new acquisition cost based reimbursement rules for covered outpatient drugs. The task group recommended the task group disband and future questions be addressed by the WG9 Medicaid Frequently Asked Questions Task Group. WG9 approved the recommendation.

- The [Medicaid Frequently Asked Questions Task Group](https://example.com) participated in a joint call with WG1 Definition of a Valid Prescriber Task Group to determine a reasonable effective date for Managed Medicaid POS provider enrollment validation and identify technical concerns for CMS. CMS did not take any action on the task group’s request to repeal or delay implementation of the Medicaid Managed Care Provider Enrollment Requirement. The task group continues to gather state Medicaid Ordering/Referring Provider requirements and work on the development of a standardized enrollment file format for state Medicaid programs.

- The [Hospice Task Group](https://example.com) did not meet this quarter.

- The [Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group](https://example.com) did not meet this quarter.
• The Medicare Prescription Drug Event (PDE) Task Group reviewed CMS-4182-P: Medicare Program; Contract Year 2019 and prepared comments for the consolidated NCPDP response; reviewed draft Chapter 14 of the Medicare Prescription Drug Benefit Manual and provided comments for the consolidated NCPDP response; reviewed 13 outstanding questions and resubmitted to CMS; discussed three new questions (PDE 870: EA Plan, Copay for Applicable Drugs in Gap, No NPP, Overriding Non-Covered PDE Rejects for Medically Accepted Indications, LICS 4 Deductible with mid-year change); finalized and closed two questions (DDPS & PRS System Updates to Accommodate SSNRI and LICS 4 Deductible with mid-year change).

• The Medicare Financial Information Reporting Task Group reviewed draft Chapter 14 of the Medicare Prescription Drug Benefit Manual and prepared comments for the consolidated NCPDP response.

• The Supplemental Payer Part D Reconciliation Standardization Task Group did not meet this quarter.

• The OIG Report OEI 05-12-00540 Task Group is on hiatus.

• The Medicare Part D FAQ Task Group reviewed CMS-4182-P: Medicare Program; Contract Year 2019 and prepared comments for the consolidated NCPDP response; reviewed the NCPDP task group assignments for the review and comment on Medicare Prescription Drug Benefit Manual Chapters 13 and 14 and finalized two questions: Question 70. Commercial Payer Subrogation (Pended by WG9 in November) and Question 141. Home Infusion Therapy which were approved for publication by WG9.

• The Medicare Card Project Task Group participated in two joint calls with CMS to discuss the task group’s request for a blackout period for MARx DTRR processing for the plans prior to the 4/1/2018 Medicare Beneficiary Identifier transition period implementation date. The task group also reviewed three new questions and responses from CMS. The task group will continue to field questions related to the Medicare Card Project and follow-up with CMS as needed.

• The Coordination of Benefits Contractor (COBC)/Benefits Coordination & Recovery Center (BCRC) Task Group collected examples of pain points encountered with Medicare Secondary Payer records to submit to CMS by the end of January. The task group also reviewed the Medicare Prescription Drug Benefit Manual, draft Chapter 14 and prepared comments for the consolidated NCPDP response.

• The Standardized Pharmacy Credentialing Task Group which was formed in November 2017 drafted proposed scope and goals for review by WG9. The task group also requested the name of the task group be changed to Standardized Pharmacy Dispenser Data Task Group to better align with the scope of the task group. WG9 approved the proposed scope/goals and name change.

New Business:

• Task Group Leader Certificates of Appreciation were presented by the WG9 Co-Chairs to the WG9 Task Group Leads.

Work Group 10 Professional Pharmacy Services

Old Business:

• An update was provided on the current status of the United States Pharmacopeia (USP) Allergy Project.

Task Groups:

• The MTM and Pharmacist Clinical Services Task Group gave an update on the eCare Plan. The HL7 comment only ballot has been completed for two implementation guides, the C-CDA and the FHIR. Comments are being reconciled for resolution. The revised Billing Guidance for Pharmacists Professional and Patient Care Services white paper was presented to and approved by the work
group with no modifications. The group also reviewed the Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program NPRM and provided suggested comments.

- The mL White Paper Task Group did not meet this quarter.
- An update was provided on the activities of the WG14 Consultant Pharmacist Interoperability Task Group.
- An update was provided on the activities of the WG11 Specialty Requirements for ePrescribing Task Group.
- An update was provided on the activities of the WG11 Implementation of Sig Task Group.

New Business:

- Rear Admiral (RADM) Pamela Schweitzer, Pharm.D., BCACP, United States Public Health Service, spoke with the work group participants to engage them in working together to develop solutions for physician to pharmacist referrals and vice versa, similar to the way physician to physician referrals currently operate. She also asked the members to begin thinking about pharmacists with advance provider status and how it will affect Medicaid enrollments.
- Task Group Leader Certificates of Appreciation were presented by the WG10 Co-Chairs to the WG10 Task Group Leads.

Work Group 11 ePrescribing & Related Transactions

Ballots Adjudicated:

- **BALLOT WG110077R** for the SCRIPT, Specialized and XML Standard is considered a valid ballot having received the required 60% of Consensus Group votes and received 75% approval rating on the recirculation ballot. Following a 30-day appeal period that begins when the ballot results are posted to the NCPDP website prior to the work group meeting, notification of the ballot results and the ballot documents will be sent to the board for approval. Should the board approve, the standard documents will be released with the date of board approval.

DERFs/ECLs Reviewed:

- DERF 001564 was pended to the WG11 SCRIPT Implementation Recommendations Task Group.
- DERF 001568 was withdrawn.
- DERF 001583 was pended to the WG11 Formulary and Benefit Task Group to work with the WG11 SCRIPT Implementation Recommendations Task Group for an ePrescribing solution.
- DERF 001584 was approved.
- DERF 001585/ECL 000258 was pended to the WG11 SCRIPT Implementation Recommendations Task Group.
- DERF 001586 was approved.
- DERF 001587 was pended to WG14 LTPAC ePrescribing Task Group.
- DERF 001588 was approved.
- DERF 001589 was approved.
- DERF 001590/ECL 000259 recommended approval to MC Maintenance and Control.

Old Business:

- Update on the next version of the SCRIPT Standard regulation was given.
- Update on electronic prescribing of controlled substance prescriptions was given.

Task Groups:

- The Biologics and Biosimilar Access and Traceability Task Group did not meet.
• The Dispensed Medication Reporting Task Group is in the review process of the needs for reporting of dispensed medication to Health Insurance Exchange (HIE) programs.

• The ePrescribing Regulatory Task Group continued discussion on the response received from the DEA on the NCPDP letter regarding RxRenewal. The task group presented their proposed guidance on RxRenewal in response to the DEA letter and the work group modified the guidance and pended it for legal review.

• The Formulary and Benefit Task Group brought forth DERFs 001583 and 001584.

• The Harmonization of Prescribing and Dispensing Units Task Group did not meet.

• The Implementation of Structured Sig Task Group focused on validating the sig examples in the SCRIPT Standard v2016071, working on FAQs. They also met with SNOMED CT® on additional codified values to be used in the structured sig.

• The Integrate S&I PDMP Guidance into SCRIPT Task Group did not meet.

• The NCPDP/HL7 Pharmacist Functional Profile Task Group brought forth questions to the work group around the recommendation pharmacy adopt the Meaningful Use 2015 EHR test criteria Functional Profile (FP). They will begin working on guidance for using the FP.

• The Prior Authorization Workflow to Transactions Task Group worked on updated website documents about electronic prior authorization.

• The REMS Workflow to Transactions Task Group finalized review and comments on the REMS Platform Standards Initiative Needs Assessment document. They will begin reviewing the Opioid Policy Steering Committee: Prescribing Intervention—Exploring a Strategy for Implementation; Public Hearing; Request for Comments.

• The SCRIPT Implementation Recommendations Task Group brought forth DERFs 001564 and 001585/ECL 000258. Received approval to change the task groups name to Electronic Prescribing Recommendations Task Group.
  - Received approval for updates to the SCRIPT Implementation Recommendations document:
    - New FAQ - How should prescribers indicate therapeutic substitution is permissible in order to comply with requirements (such as Arkansas) in SCRIPT 10.6?
    - New FAQ - If a Refill approval response is returned with 3 Refills authorized for the quantity requested, how should this be interpreted by the pharmacy? As a total quantity of 4 fills (the 30 in the original request + 3 refills of 30 for a total quantity of 120; or as 3 fills total of the quantity in the request for total quantity of 90)?
    - New FAQ - How should the RelatesToMessageID in the RxFill message be populated?
    - Update to Section: Digital Signatures
  - Received approval of an Opioid Fact Sheet.

• The SCRIPT Managed Updates Schedule Task Group disbanded.

• The Specialty Requirements for ePrescribing Task Group continued looking into the creation of an intake form.

• The WG14 LTPAC ePrescribing Task Group brought forth DERF 001568.

• The X12 270/271 version 7030 Review Task Group did not meet. The X12 270/271 TR3 release has been delayed.

• The XML Task Group reviewed all submitted DERFs and provided recommendations for them.

New Business:
• **Task Group Leader Certificates of Appreciation** were presented by the WG11 Co-Chairs to the WG11 Task Group Leads.

**WG14 Long Term and Post Acute Care (LTPAC)**

**Old Business:**
- An Industry Update was provided on the status of NPRM released in November 2017. An overview of the NPRM was presented and the work group’s suggested comments were discussed. The recently released call letter and its implications on the billing of certain ESRD drugs, as well as opioids as it related to Long Term Care, were also examined.

**Task Groups:**
- The **LTPAC Current Billing Issues Task Group** submitted DERF 001581/ECL 000257 which was approved in WG1 Telecommunication with modifications and approved with no further modifications in MC Maintenance and Control. The task group also submitted DERF 001582 which was approved with no modifications in WG1 Telecommunication and MC Maintenance and Control.
- The **Long Term and Post Acute Care ePrescribing Task Group** brought forth DERF 001568 which was withdrawn by the submitter. The group continues to develop guidance for LTPAC use of SCRIPT and to propose changes for inclusion in future versions. The will also work on a request from NIST Use Case Sub-Task Group to create testing use cases for Resupply, DrugAdministration, Recertification and Census messages for 2017071.
- The **Consultant Pharmacist Interoperability Task Group** announced the [C-CDA Consult Note Guidance Document](#) has been finalized and published on the NCPDP website. The Consult Note provides consultant pharmacists a means for documenting and sharing their recommendations electronically with providers. The task group is working to gather participants for a pilot. The pilot will include a pharmacist consultant software, LTC facility EHR system, and LTC physician EHR system.
- **Task Group Leader Certificates of Appreciation** were presented by the WG14 Co-Chairs to the WG14 Task Group Leads.

**Work Group 16 Property & Casualty/Workers Compensation**

**Task Groups:**
- The **Legislative/Regulatory Monitoring and Education Task Group** provided updates on state regulatory and legislative initiatives affecting Workers’ Compensation programs for several states including Alabama, Arkansas, Arizona, California, Hawaii, Indiana, Massachusetts, North Carolina, New York, Texas, Wisconsin and Wyoming.
- The **Billing and State Reporting Task Group** provided an update on New Jersey and Tennessee eBilling rules.
- The **Future Development Needs for WC/PC Task Group** did not meet this quarter. This task group will begin meeting once next versions of both NCPDP and relevant X12 TR3s are finalized to identify WC needs and develop strategies to meet those needs. Members were asked to submit any known issues for consideration.

**New Business:**
- Carlos Luna, Director of Government Affairs of Reed Group and IAIABC Committee Member provided a presentation to the work group on the recent implementation of the new California Medical Treatment Utilization (MTUS) Workers’ Compensation Drug Formulary.
- **Task Group Leader Certificates of Appreciation** were presented by the WG16 Co-Chairs to the WG16 Task Group Leads.
Work Group 45 External Standards Assessment, Harmonization and Implementation Guidance

Old Business:
- Industry updates were provided for WEDI, NCPDP SNIP, CAQH CORE, X12 and Health Exchanges.

Task Groups:
- The Document Revision Task Group reviewed new and revised CARCs and usage notes which were approved by the Code Committee at the X12 September 2017 meeting. The task group formulated recommendations and updated the CARC Mapping document for approval. The updated mapping document was presented to the work group, approved with no modifications and will now undergo the Inter SDO process for review and publication on the NCPDP website. It was noted that the Telecommunication Version F2 and X12 7030 implementation timelines will differ, and it is important for members to stay engaged. The task group has forthcoming work updating NCPDP documentation for F2 as well as sync with X12 7030.
- The Pharmacy and/or Combination ID Card Task Group did not meet this quarter.
- The X12 7030 834/835 TR3 Review Task Group discussed clarifying language for reporting overpayment recovery at the claim level.
- The 834/835 FAQ Task Group did not meet this quarter.
- The DSMO Task Group received no DSMO requests for review.
- The DIR 835 Reporting Task Group continues work on examples and also gave an update of the CARC 295 for PHARMACY DIRECT/INDIRECT REMUNERATION (DIR) that was submitted and approved at the January 2018 Code Committee Meeting in Portland.

New Business:
- Task Group Leader Certificates of Appreciation were presented by the WG45 Co-Chairs to the WG45 Task Group Leads.

MC Maintenance and Control
DERFs/ECLs Reviewed: 12 new and 4 pended DERFs/ECLs (see WG1, WG11, and MC).
- DERF 001559/ECL 000248 was approved with no further modifications.
- DERF 001564 was pended.
- DERF 001568 was withdrawn by the submitter.
- DERF 001576/ECL 000252 was pended.
- DERF 001579/ECL 000255 was approved with no further modifications.
- DERF 001580/ECL 000256 was approved.
- DERF 001581/ECL 000257 was approved with no further modifications.
- DERF 001582 was approved.
- DERF 001583 was pended.
- DERF 001584 was approved.
- DERF 001585/ECL 000258 was pended.
- DERF 001586 was approved
- DERF 001587 was pended.
- DERF 001588 was approved.
- DERF 001589 was approved.
- DERF 001590/ECL 000259 was approved.

Old Business:
- Received updates on:
  - Board of Trustees
Task Groups:

- **Education/Legislation and Regulations Task Group** finalized comments for 2017 ONC Interoperability Standards Advisory. The task group also finalized comments for the Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program NPRM. The comments for the NPRM were a result of a coordinated effort across seven task groups from four different work groups.

- **Real Time Prescription Benefit Standard Task Group** completed the EDI format transaction layout. Examples for the majority of the original task group’s use cases have been aligned to the layout to confirm it structurally meets the needs of each business case.

- **API Task Group** is focusing on an update to the NCPDP Connectivity Operating Rules in relation to API’s. A DERF to update the Rules document has been drafted and will be submitted for the May WG meeting.

- **Emergency Preparedness Task Group** reviewed the NCPDP Emergency Preparedness Document v1.4 to ensure all Emergency Preparedness information was current and accurate. A new version of the document has been prepared.

- **X12 TR3 Comment Consolidation Task Group** did not meet this quarter.

- **ECL Task Group** finalized the best practice guidance for ECL and Emergency ECL DERF submission after additional changes were requested. The task group decided to expand the existing description for “other” as needed to clearly define when the value is to be used.

- **Specialty Task Group** receives regular updates from task groups with activity which either specifically targets specialty workflows or work that may impact/benefit specialty stakeholders. The task group reviewed website activity and agreed to monitor industry educational activity as identified/reported by task group members.

- **2D Barcode Implementation Task Group** did not receive any questions on their published white paper. The task group’s request to disband since their assigned work is completed was approved by the Work Group.

- **Gender Transition Task Group** reviewed gender edits from payers and the need to have an override. Additional documentation was presented in support of pending DERF 001576/ECL 000252 which introduces a new Submission Clarification Code to allow pharmacies to override gender rejects when the pharmacy determines the reject is invalid for patients transitioning genders.

- **Patient Identification Task Group** completed the creation of universal use cases to outline the communication of universal patient identifiers (UPIs) within the NCPDP Standards.

New Business:

- The attendees received recaps of each Work Group’s activities.

- **Task Group Leader Certificates of Appreciation** were presented by the MC Co-Chairs to the MC Task Group Leads.

- NCPDP Most Valuable Participants were announced.